PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 31, 2026Molecular Brain2 citationsOpen Access

m6A RNA methylation in neural plasticity, brain aging, and neurodegenerative vulnerability

XZXuehua ZhouPYPeng YuXSXia Shen

Key Points

  • To explore the role of m6A RNA methylation in neural plasticity, brain aging, and vulnerability to neurodegenerative diseases.
  • Review of literature on m6A RNA methylation and its functions in the brain
  • Analysis of its roles in development, synaptic function, and activity-dependent plasticity
  • Investigation of age-related changes in m6A regulation across different cell types
  • Examination of alterations in m6A during various neurodegenerative diseases
  • m6A regulates important processes including RNA splicing, stability, and translation in neurons and glial cells
  • Aging leads to reconfigurations in m6A programs, correlating with reduced neural plasticity
  • Disease-associated m6A alterations contribute to disruptions in signaling pathways and overall synaptic integrity

Abstract

Abstract m6A is a pervasive post-transcriptional RNA modification that regulates RNA splicing, stability, localization, and translation in the brain. In this review, we outline the core m6A regulatory machinery and summarize its spatial organization across neurons and glial cells, highlighting established roles in brain development, synapse formation, and axon growth. We then focus on experience-dependent plasticity, synthesizing evidence that neuronal activity and environmental inputs dynamically reshape m6A to regulate immediate-early transcription and local translation at synapses across sensory, cognitive, emotional, and motor domains. With aging, m6A programs are reconfigured in a cell-type–specific manner, a shift associated with reduced plasticity and increased vulnerability. We further survey disease-associated alterations in m6A across Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, stroke-related cognitive impairment, ALS and FTD, as well as metal or toxin exposure, emphasizing convergent effects on dopaminergic and glutamatergic signaling, synaptic integrity, inflammation, and cellular stress responses. Finally, we discuss emerging opportunities and conceptual challenges in targeting m6A enzymes or reader proteins, and outline priorities for future work, including cell-type– and subcellular-resolved mapping, causal perturbation in defined circuits and life stages, and the development of biomarkers and selective modulators. Together, these observations position m6A as a molecular interface linking experience-dependent plasticity, brain aging, and neurodegenerative vulnerability. Graphical abstract

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Zhou et al. (2026) studied this question.

synapsesocial.com/papers/69cb64f0e6a8c024954b9086https://doi.org/10.1186/s13041-026-01297-z
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1m6A RNA Methylation in Psychiatric Disorders: An Emerging Epitranscriptomic Axis2025 · 8 citations
  2. 2The m6A Modification in Neurodegenerative Disease: A Cellular Perspective2025
  3. 3The epitranscriptomic m6A RNA modification modulates the synapse in ageing and in a mouse model of synucleinopathy2026 · 1 citations
  4. 4Studying m6A in the brain: a perspective on current methods, challenges, and future directions2024 · 4 citations
  5. 5The epitranscriptomic m6A RNA modification modulates synaptic function in ageing and in a mouse model of synucleinopathy2024